Rhabdomyolysis in a patient receiving atorvastatin and fluconazole

European Journal of Clinical Pharmacology

Volumn 60, Issue 12, 2005, Pages 905-907

  Kahri, Juhani ^a   Valkonen, Miia ^a   Bäcklund, Tom ^a   Vuoristo, Matti ^a   Kivistö, Kari T ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Atorvastatin; Fluconazole; Rhabdomyolysis

Indexed keywords

ANTIINFECTIVE AGENT; ATORVASTATIN; BISOPROLOL; DIGOXIN; DOPAMINE; DOXYCYCLINE; ESOMEPRAZOLE; FLUCONAZOLE; FUROSEMIDE; FUSIDIC ACID; HEPARIN; INOTROPIC AGENT; PRAVASTATIN; PREDNISOLONE; WARFARIN;

AGED; ANAMNESIS; ANTIMICROBIAL THERAPY; ANURIA; AORTA ANEURYSM; AORTA RUPTURE; AORTA STENOSIS; ARTICLE; CASE REPORT; CAUSE OF DEATH; CHRONICITY; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FEVER; FOLLOW UP; GRAFT INFECTION; HEART ATRIUM FIBRILLATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LABORATORY TEST; MALAISE; MALE; MULTIPLE ORGAN FAILURE; OLIGURIA; PRIORITY JOURNAL; RHABDOMYOLYSIS;

ANTIFUNGAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG SYNERGISM; FATAL OUTCOME; FLUCONAZOLE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYCOSES; PYRROLES; RHABDOMYOLYSIS;

EID: 15244362032     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0858-5     Document Type: Article

References (16)

1. Ucar M, Mjorndal T, Dahlqvist R (2000) HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 22:441-457
2. Omar MA, Wilson JP, Cox TS (2001) Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35:1096-1107
3. Thompson PD, Clarkson P, Karas RH (2003) Statin-associated myopathy. JAMA 289:1681-1690
4. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JD (2002) Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581-585
5. Williams D, Feely J (2002) Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41:343-370
6. Omar MA, Wilson JP (2002) FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 36:288-295
7. Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wetzler M, Baer MR (2003) Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 37:1032-1035
8. Neuvonen PJ, Kantola T, Kivisto KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:332-341
9. Back DJ, Tjia JF (1991) Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 32:624-626
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239-245
11. Kantola T, Kivisto KT, Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58-65
12. Venkatakrishnan K, von Moltke LL, Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38:111-180
13. Varhe A, Olkkola KT, Neuvonen PJ (1996) Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 42:465-470
14. De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E (2004) A to Z Investigators, early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292:1307-1316
15. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285:1711-1718
16. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495-1504